Amphion Innovations plc
New Debt Facility

London and New York, 15 April 2011– Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, today announces it has secured additional unsecured loan financing of $500,000 from R. James Macaleer, Chairman of Amphion, who is interested in 17.12% of the issued share capital of the Company. Mr. Macaleer will also receive 500,000 five year warrants at an exercise price of 11.25 pence. The loan is repayable on 31 January 2012 and carries interest at 5% per annum.

This transaction is deemed a related party transaction for the purposes of the AIM Rules. As a result, the Independent Directors consider, having consulted with the Company’s nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.

For further information please contact:
Amphion Innovations plc
Charlie Morgan
+1 212 210 6224

Cardew Group
Tim Robertson
+44 (0)20 7930 0777

Seymour Pierce Limited, Nominated Advisor
Freddy Crossley/ Mark Percy
+44 (0)20 7107 8000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number that grows rapidly each year.

On the web: